Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 2/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 4/20 | 0.52 |
| ▸ | BCHE | P06276 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8790306 | 0.94 | CYP19A1 (0.61) | CYP19A1CYP1A2CYP3A4CYP2D6KDM4E | |
| SCHEMBL8789804 | 0.88 | CYP19A1 (0.67) | CYP19A1CYP1A2CYP3A4CYP2D6KDM4E | |
| SCHEMBL3153112 | 0.88 | KDM4E (0.72) | CYP19A1CYP1A2CYP3A4CYP2D6KDM4E | |
| SCHEMBL3149514 | 0.85 | CYP19A1 (0.66) | CYP19A1KDM4ESMN1; SMN2AOC3ALDH1A1 | |
| SCHEMBL8789870 | 0.85 | CYP19A1 (0.63) | CYP19A1CYP1A2CYP3A4CYP2D6KDM4E | |
| SCHEMBL11318983 | 0.84 | CYP19A1 (0.54) | CYP19A1CYP1A2CYP3A4CYP2D6KDM4E | |
| SCHEMBL8790080 | 0.84 | CYP19A1 (0.54) | CYP19A1CYP1A2CYP3A4CYP2D6KDM4E | |
| SCHEMBL8790086 | 0.84 | CYP19A1 (0.61) | CYP19A1CYP1A2CYP3A4CYP2D6KDM4E | |
| SCHEMBL8790071 | 0.84 | CYP19A1 (0.54) | CYP19A1CYP1A2CYP3A4CYP2D6KDM4E | |
| SCHEMBL3151848 | 0.84 | CYP19A1 (0.61) | CYP19A1KDM4EATMAOC3ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1224170-B9 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA (DE) | 2017-11-22 | — | — | EP | disclosed |
| EP-2157081-A1 | Indolinones substituted in six locations, their manufacture and their application as medicine | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2010-02-24 | — | — | EP | disclosed |
| EP-1224170-B1 | 6-POSITION SUBSTITUTED INDOLINE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA (DE) | 2009-08-12 | — | — | EP | disclosed |
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| CN-100338036-C | Substituted indolinones with inhibitory effect on kinase and cyclin complexes | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-09-19 | — | — | CN | disclosed |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
| US-6762180-B1 | Substituted indolines which inhibit receptor tyrosine kinases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-07-13 | — | — | US | disclosed |
| EP-1071665-B1 | SUBSTITUTED INDOLINONES HAVING AN INHIBITING EFFECT ON KINASES AND CYCLINE/CDK COMPLEXES | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-10-01 | — | — | EP | disclosed |
| US-6545035-B1 | Having effect on various kinases and cycline/CDK complexes and on the proliferation of various tumour cells. | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-04-08 | — | — | US | disclosed |
| CN-1391557-A | 6-substituted indolinones, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA (DE) | 2003-01-15 | — | — | CN | disclosed |
| US-6319918-B1 | FOR LYMPHOMA OR SOLID TUMORS TREATMENT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-11-20 | — | — | US | disclosed |
| CN-1303374-A | Substituted indolinones, process for their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA (DE) | 2001-07-11 | — | — | CN | disclosed |
| US-6169106-B1 | ANTITUMOUR AGENTS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-01-02 | — | — | US | disclosed |
| US-5663179-A | CAN SENSITIZE MULTIDRUG RESISTANT CANCER CELLS TO CHEMOTHERAPEUTIC AGENTS | LABORATOIRES GLAXO SA (FR) | 1997-09-02 | — | — | US | disclosed |
| EP-0649410-B1 | ANILIDE DERIVATIVES | GLAXO LAB SA (FR) | 1997-05-02 | — | — | EP | disclosed |
| EP-0649410-A1 | ANILIDE DERIVATIVES. | GLAXO LAB SA (FR) | 1995-04-26 | — | — | EP | disclosed |
| WO-1994001408-A1 | ANILIDE DERIVATIVES | LABORATOIRES GLAXO S.A. (FR) | 1994-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | KDR, FLT1, EGFR | CYP19A1 296/4885CYP1A2 505/4885CYP3A4 441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.